Chemical formula: C₉H₁₂ClN₅O Molecular mass: 241.677 g/mol PubChem compound: 4810
Moxonidine interacts in the following cases:
Since tricyclic antidepressants may reduce the effectiveness of centrally acting antihypertensive agents, it is not recommended that tricyclic antidepressants be co-administered with moxonidine. Moxonidine can potentiate the sedative effect of tricyclic anti-depressants (avoid co-prescribing).
Moxonidine can potentiate the sedative effect of tranquillisers, alcohol, sedatives and hypnotics.
In patients with moderately impaired renal function (GFR >30 ml/min but <60 ml/min), the single dose should be not more than 0.2 mg and the daily dose not more than 0.4 mg moxonidine.
Concomitant administration of moxonidine and other antihypertensive agents result in an additive effect.
If moxonidine is used in combination with a β-blocker and both treatments have to be discontinued, the β-blocker should be discontinued first, and then moxonidine after a few days.
Moxonidine may enhance the sedative effect of benzodiazepines when administered concomitantly.
NSAIDs antagonize the hypotensive effect of moxonidine.
Moxonidine moderately augmented the impaired performance in cognitive functions in subjects receiving lorazepam.
Depending on the dose of tolazoline, it may reduce or even neutralize the effect of moxonidine.
When moxonidine is used in patients with 1st degree AV block, special care should be exercised to avoid bradycardia.
There are no adequate data from use of moxonidine in pregnant women. Studies in animals have shown embryo-toxocological effects. The potential risk for humans is unknown. Moxonidine should not be used during pregnancy unless clearly necessary.
Moxonidine should not be used during lactation as moxonidine is excreted in breast milk. If therapy with moxonidine is considered absolutely necessary, the breast feeding shall be stopped.
The effect of moxonidine on the ability to drive or use machines has not been studied. Since, however, there have been reports of drowsiness and dizziness, the patient should exercise caution with regard to hazardous activities such as driving or using machines.
Especially at the beginning of treatment dry mouth, headache, somnolence, asthenia and dizziness have been described frequently. The frequency and intensity of these symptoms often disappear in the course of treatment.
Undesirable Effects by System Organ Class: (observed during placebo-controlled clinical trials with n=886 patients exposed to moxonidine resulted in frequencies below):
Very common: ≥1/10, Common: ≥1/100 to <1/10, Uncommon: ≥1/1,000 to <1/100, Rare ≥1/10,000 to <1/1,000, Very rare <1/10,000, Not known (cannot be estimated from the available data).
* there was no increase in frequency compared to placebo
Uncommon: Bradycardia
Uncommon: Tinnitus
Common: Headache*, dizziness, somnolence, vertigo
Uncommon: Syncope*
Uncommon: Hypotension (including orthostatic)
Very common: Dry mouth
Common: Nausea, diarrhoea, vomiting, dyspepsia
Common: Rash, pruritus
Uncommon: Angioedema
Common: Asthenia
Uncommon: Oedema
Common: Back pain
Uncommon: Neck pain
Common: Insomnia
Uncommon: Nervousness
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
